HRP20190250T1 - Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije - Google Patents
Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije Download PDFInfo
- Publication number
- HRP20190250T1 HRP20190250T1 HRP20190250TT HRP20190250T HRP20190250T1 HR P20190250 T1 HRP20190250 T1 HR P20190250T1 HR P20190250T T HRP20190250T T HR P20190250TT HR P20190250 T HRP20190250 T HR P20190250T HR P20190250 T1 HRP20190250 T1 HR P20190250T1
- Authority
- HR
- Croatia
- Prior art keywords
- newcastle disease
- disease virus
- attenuated newcastle
- virus
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361873039P | 2013-09-03 | 2013-09-03 | |
| PCT/EP2014/068619 WO2015032755A1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
| EP14761317.8A EP3041490B1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190250T1 true HRP20190250T1 (hr) | 2019-05-31 |
Family
ID=51492938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220653TT HRP20220653T1 (hr) | 2013-09-03 | 2014-09-02 | Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije |
| HRP20190250TT HRP20190250T1 (hr) | 2013-09-03 | 2014-09-02 | Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220653TT HRP20220653T1 (hr) | 2013-09-03 | 2014-09-02 | Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10519426B2 (OSRAM) |
| EP (3) | EP3508209B1 (OSRAM) |
| JP (2) | JP6557234B2 (OSRAM) |
| KR (2) | KR102285894B1 (OSRAM) |
| CN (2) | CN111944767A (OSRAM) |
| AU (2) | AU2014317215C1 (OSRAM) |
| CA (1) | CA2922071C (OSRAM) |
| CY (2) | CY1121993T1 (OSRAM) |
| DK (2) | DK3041490T3 (OSRAM) |
| EA (2) | EA202191926A3 (OSRAM) |
| ES (2) | ES2914577T3 (OSRAM) |
| HK (2) | HK1231393A1 (OSRAM) |
| HR (2) | HRP20220653T1 (OSRAM) |
| HU (1) | HUE042382T2 (OSRAM) |
| LT (2) | LT3041490T (OSRAM) |
| ME (1) | ME03345B (OSRAM) |
| MX (2) | MX367768B (OSRAM) |
| PL (2) | PL3041490T3 (OSRAM) |
| PT (2) | PT3041490T (OSRAM) |
| RS (2) | RS63291B1 (OSRAM) |
| SI (2) | SI3508209T1 (OSRAM) |
| SM (2) | SMT202200214T1 (OSRAM) |
| TR (1) | TR201902073T4 (OSRAM) |
| TW (1) | TWI653334B (OSRAM) |
| WO (1) | WO2015032755A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG176468A1 (en) | 2005-12-02 | 2011-12-29 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
| WO2010091262A1 (en) | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
| JP6596411B2 (ja) | 2013-03-14 | 2019-10-23 | アイカーン スクール オブ メディシン アット マウント サイナイ | ニューカッスル病ウイルス及びその使用 |
| EA202191926A3 (ru) * | 2013-09-03 | 2022-01-31 | Медиммун Лимитед | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии |
| KR102407019B1 (ko) | 2014-02-27 | 2022-06-08 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 결합 방법 |
| EP3288595B1 (en) * | 2015-04-28 | 2020-12-30 | The University Of Georgia Research Foundation, Inc. | Piv5-based amplifying virus-like particles |
| US10626377B2 (en) | 2016-01-08 | 2020-04-21 | Replimune Limited | Use of an oncolytic virus for the treatment of cancer |
| EP3246410A1 (en) * | 2016-05-19 | 2017-11-22 | Klinikum rechts der Isar der Technischen Universität München | Vsv/ndv hybrid viruses for oncolytic therapy of cancer |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| KR101964610B1 (ko) * | 2017-03-13 | 2019-04-03 | 대한민국 | 신규한 종양용해성 바이러스 및 이의 용도 |
| JOP20190256A1 (ar) * | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CN107254450A (zh) * | 2017-07-20 | 2017-10-17 | 扬州大学 | 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法 |
| CN108486279A (zh) * | 2017-09-21 | 2018-09-04 | 山东省农业科学院家禽研究所 | 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法 |
| EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
| CA3106170A1 (en) * | 2018-07-13 | 2020-01-16 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| JP2023518295A (ja) * | 2020-03-20 | 2023-04-28 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| CN115197949A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途 |
| US20220396809A1 (en) * | 2021-06-03 | 2022-12-15 | University Of Guelph | Engineered newcastle disease virus vector and uses thereof |
| US20240287544A1 (en) * | 2023-02-06 | 2024-08-29 | Cyanvac Llc | Modified piv5 vaccine vectors: methods of making and uses |
| WO2025116613A1 (ko) * | 2023-11-29 | 2025-06-05 | 주식회사 카브 | 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7724558B1 (en) * | 1999-03-19 | 2010-05-25 | Nec Corporation | Magnetic signal transmission line |
| AU7607900A (en) * | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| KR100801180B1 (ko) * | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| US20090208495A1 (en) | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| WO2010091262A1 (en) * | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
| JP6596411B2 (ja) * | 2013-03-14 | 2019-10-23 | アイカーン スクール オブ メディシン アット マウント サイナイ | ニューカッスル病ウイルス及びその使用 |
| EA202191926A3 (ru) * | 2013-09-03 | 2022-01-31 | Медиммун Лимитед | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии |
| CN109099045A (zh) * | 2018-10-30 | 2018-12-28 | 浙江斯泰新材料科技股份有限公司 | 防松锁固型螺钉 |
-
2014
- 2014-09-02 EA EA202191926A patent/EA202191926A3/ru unknown
- 2014-09-02 ES ES18188565T patent/ES2914577T3/es active Active
- 2014-09-02 SM SM20220214T patent/SMT202200214T1/it unknown
- 2014-09-02 DK DK14761317.8T patent/DK3041490T3/en active
- 2014-09-02 KR KR1020167008307A patent/KR102285894B1/ko active Active
- 2014-09-02 HU HUE14761317A patent/HUE042382T2/hu unknown
- 2014-09-02 CN CN202010064863.0A patent/CN111944767A/zh active Pending
- 2014-09-02 EA EA201690425A patent/EA039404B1/ru unknown
- 2014-09-02 JP JP2016537333A patent/JP6557234B2/ja active Active
- 2014-09-02 EP EP18188565.8A patent/EP3508209B1/en active Active
- 2014-09-02 PL PL14761317T patent/PL3041490T3/pl unknown
- 2014-09-02 EP EP14761317.8A patent/EP3041490B1/en active Active
- 2014-09-02 HR HRP20220653TT patent/HRP20220653T1/hr unknown
- 2014-09-02 PT PT14761317T patent/PT3041490T/pt unknown
- 2014-09-02 ME MEP-2019-40A patent/ME03345B/me unknown
- 2014-09-02 TR TR2019/02073T patent/TR201902073T4/tr unknown
- 2014-09-02 SI SI201431957T patent/SI3508209T1/sl unknown
- 2014-09-02 HK HK17105137.4A patent/HK1231393A1/zh unknown
- 2014-09-02 HR HRP20190250TT patent/HRP20190250T1/hr unknown
- 2014-09-02 CN CN201480048630.4A patent/CN106163532B/zh active Active
- 2014-09-02 CA CA2922071A patent/CA2922071C/en active Active
- 2014-09-02 PL PL18188565T patent/PL3508209T3/pl unknown
- 2014-09-02 KR KR1020217012332A patent/KR102310692B1/ko active Active
- 2014-09-02 SM SM20190094T patent/SMT201900094T1/it unknown
- 2014-09-02 AU AU2014317215A patent/AU2014317215C1/en active Active
- 2014-09-02 SI SI201431082T patent/SI3041490T1/sl unknown
- 2014-09-02 RS RS20220481A patent/RS63291B1/sr unknown
- 2014-09-02 US US14/916,102 patent/US10519426B2/en active Active
- 2014-09-02 RS RS20190176A patent/RS58332B1/sr unknown
- 2014-09-02 PT PT181885658T patent/PT3508209T/pt unknown
- 2014-09-02 WO PCT/EP2014/068619 patent/WO2015032755A1/en not_active Ceased
- 2014-09-02 LT LTEP14761317.8T patent/LT3041490T/lt unknown
- 2014-09-02 ES ES14761317T patent/ES2708755T3/es active Active
- 2014-09-02 DK DK18188565.8T patent/DK3508209T3/da active
- 2014-09-02 EP EP22160157.8A patent/EP4101457A1/en not_active Withdrawn
- 2014-09-02 LT LTEP18188565.8T patent/LT3508209T/lt unknown
- 2014-09-02 HK HK16114099.3A patent/HK1225643B/en unknown
- 2014-09-02 MX MX2016002771A patent/MX367768B/es active IP Right Grant
- 2014-09-03 TW TW103130466A patent/TWI653334B/zh active
-
2016
- 2016-03-02 MX MX2019010364A patent/MX2019010364A/es unknown
-
2019
- 2019-02-08 CY CY20191100170T patent/CY1121993T1/el unknown
- 2019-06-24 AU AU2019204419A patent/AU2019204419B2/en active Active
- 2019-07-11 JP JP2019129161A patent/JP6862500B2/ja not_active Expired - Fee Related
- 2019-11-14 US US16/684,241 patent/US11471499B2/en active Active
-
2022
- 2022-05-25 CY CY20221100362T patent/CY1126790T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190250T1 (hr) | Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije | |
| JP2019193662A5 (OSRAM) | ||
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| JP2016533749A5 (OSRAM) | ||
| HRP20240078T1 (hr) | Imuno-onkolitičke terapije | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MX379423B (es) | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| HRP20231025T1 (hr) | Onkolitički virus vakcinije | |
| MX2020013249A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| MX2015012891A (es) | Composiciones y metodos de variantes de inhibidor tisular de la metaloproteinasa tipo tres (timp-3). | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| EA202191602A3 (ru) | Не содержащая сыворотки среда для культивирования клеток | |
| DK3981414T3 (da) | Lyofiliserede præparater med højt overfladeareal, der indeholder arsenik til oral indgivelse i patienter | |
| MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
| MX2015017852A (es) | Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma. | |
| WO2014169882A3 (zh) | 具有抗肿瘤活性的苯并咪唑类化合物、制备方法及其应用 | |
| CL2017001088A1 (es) | Regimen de dosificación para interferón pegilado | |
| MX2021007643A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| Abdolreza et al. | < The> effect of endurance training on MiR-155 expression, STAT3 gene expression, and interleukin 6 protein in mice with breast cancer | |
| CN103653183A (zh) | 一种口服液防腐保鲜剂 | |
| MX2019013161A (es) | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. | |
| LIU et al. | Efficacy of propofol compared with sevoflurane on inflammatory factor and liver function after hepatectomy | |
| Zamitiz Gamboa | Political Philosophy, fundamental component of Political Science: meanings, relations and challenges in the XXI century | |
| Toledo Filho | Statute of limitation of labor actions: substance and form issues |